KROS - Keros Therapeutics  - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

KROS is currently covered by 9 analysts with an average price target of $31.01. This is a potential upside of $16.44 (112.83%) from yesterday's end of day stock price of $14.57.

Keros Therapeutics 's activity chart (see below) currently has 27 price targets and 57 ratings on display. The stock rating distribution of KROS is 89.47% BUY and 10.53% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 29.88% with an average time for these price targets to be met of 46.3 days.

Highest price target for KROS is $26, Lowest price target is $15, average price target is $23.33.

Most recent stock forecast was given by GREG HARRISON from SCOTIABANK on 12-May-2025. First documented stock forecast 04-May-2020.

Currently out of the existing stock ratings of KROS, 34 are a BUY (89.47%), 4 are a HOLD (10.53%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$26

$11.93 (84.79%)

$41

11 days ago
(12-May-2025)

1/6 (16.67%)

$12.26 (89.23%)

215

Buy

$25

$10.93 (77.68%)

$40

15 days ago
(08-May-2025)

1/14 (7.14%)

$10.98 (78.32%)

113

Buy

$25

$10.93 (77.68%)

$43

1 months 14 days ago
(09-Apr-2025)

0/6 (0%)

$14.67 (142.01%)

Buy

$26

$11.93 (84.79%)

$111

2 months 26 days ago
(27-Feb-2025)

1/3 (33.33%)

$15.06 (137.66%)

74

Buy

$15

$0.93 (6.61%)

$105

4 months 6 days ago
(17-Jan-2025)

5/12 (41.67%)

$4.14 (38.12%)

43

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is KROS (Keros Therapeutics ) average time for price targets to be met?

On average it took 46.3 days on average for the stock forecasts to be realized with a an average price target met ratio 29.88

Which analyst has the current highest performing score on KROS (Keros Therapeutics ) with a proven track record?

JOSEPH CATANZARO

Which analyst has the most public recommendations on KROS (Keros Therapeutics )?

Joseph Catanzaro works at PIPER SANDLER and has 11 price targets and 7 ratings on KROS

Which analyst is the currently most bullish on KROS (Keros Therapeutics )?

Thomas Smith with highest potential upside - $31.36

Which analyst is the currently most reserved on KROS (Keros Therapeutics )?

Julian Harrison with lowest potential downside - -$0

Keros Therapeutics  in the News

Keros Reinforces Commitment to Maximizing Stockholder Value

Responds to Recent Public Stockholder Communications Urges Stockholders to Protect Their Investment by Voting “FOR” the Company’s Highly Qualified Director Nominees LEXINGTON, Mass., May 08, 2025 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros”, the “Company” or “we”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?